Elos Medtech Interim Report January 1 - September 30, 2022

July – September 2022

• Net sales for the third quarter amounted to SEK 231.5 (187.2) million, an increase of 23.7 percent compared to the same quarter last year. Net sales in local currencies increased by 12.4 percent.
• Operating profit amounted to SEK 37.7 (24.2) million, corresponding to an operating margin of 16.3 (12.9) percent. Operating profit in the previous year includes a charge of SEK 11.8 million related to transaction costs in connection with the completion of the offer from the new majority owner.
• Profit after net financial items amounted to SEK 29.0 (23.3) million. Net financial items were negatively affected by exchange rates of SEK -5.3 (1.5) million and totaled SEK -8.7 (-1.0) million.
• Profit after tax amounted to SEK 21.9 (17.6) million.
• Cash flow from operating activities was SEK 55.3 (12.9) million, and SEK 25.6 (1.5) million after investments.
• Earnings per share amounted to SEK 2.71 (2.18).

For further information, please contact:
Stefano Alfonsi, President and CEO, +44 772 04 98 342 , e-mail: stefano.alfonsi@elosmedtech.com
Ewa Linsäter, Group CFO, +46 76 633 32 33, e-mail: ewa.linsater@elosmedtech.com

This disclosure contains information that Elos Medtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on October 21, 2022, at 15:00 (CET). 

For additional information about the Elos Medtech Group, visit www.elosmedtech.com

Tags: